1CM
RCUS icon

1492 Capital Management’s Arcus Biosciences RCUS Stock Holding History

1492 Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30,733
Closed -$561K – 112
2023
Q1 		$561K Sell
30,733
-11
-0% -$210 0.35% 68
2022
Q4 		$636K Hold
30,744
– – 0.41% 70
2022
Q3 		$804K Sell
30,744
-6
-0% -$159 0.58% 58
2022
Q2 		$779K Buy
+30,750
New +$753K 0.51% 66

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

1492 Capital Management's RCUS Position: Q2 2023 in Review

1492 Capital Management sold out of Arcus Biosciences (RCUS) in Q2 2023, closing a stake of 30,733 shares — an estimated $561K sold.

1492 Capital Management first reported a position in RCUS in Q2 2022 and held it in 4 quarters. The position peaked at $804K in Q3 2022. 181 funds tracked by Wall St. Rank hold RCUS as of Q2 2023.

  • 1492 Capital Management reported no remaining Arcus Biosciences position as of Q2 2023 after selling out during the quarter.
  • 1492 Capital Management sold 30,733 Arcus Biosciences shares in Q2 2023, an estimated $561K.
  • 1492 Capital Management first reported a position in Arcus Biosciences in Q2 2022 and held it in 4 quarters.
  • 1492 Capital Management's Arcus Biosciences position peaked at $804K in Q3 2022.
  • 181 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2023.

Based on 1492 Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.